Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04585308
Other study ID # CLP-05-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 15, 2020
Est. completion date March 13, 2023

Study information

Verified date November 2023
Source TransAortic Medical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the safety and performance of the transShield Embolic Protection System (EPS) used for embolic protection during Transcatheter Aortic Valve Replacement (TAVR).


Description:

This is a prospective, multi-center, single arm feasibility study to assess the safety and performance of the transShield EPS. Patients with severe native aortic valve stenosis scheduled for TAVR will be screened for study eligibility. Subjects who meet the commercially approved indications for TAVR and comply with the study inclusion/exclusion criteria are eligible for enrollment. Patients will be followed for 30 days post procedure.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date March 13, 2023
Est. primary completion date March 13, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must meet all of the following criteria to be eligible for participation in the study: - Patient is >18 years old - Patient is scheduled for percutaneous TAVR with up to 20French compatible commercial TAVR system - Patient meets indications for TAVR per the device Instructions For Use - The diameter of the artery at the site of the filter placement is between 28 mm and 42 mm - Size and condition of the femoral artery iliac arteries are appropriate for the 12French transShield Expandable Introducer and 20F Embolic Protection Device - Patient, or authorized representative, signs a written Informed Consent form to participate in the study, prior to any study mandated procedures - Patient is willing and able to complete follow-up requirements Exclusion Criteria: - Patients must be EXCLUDED from participation in this study if any of the following criteria are met: - Patient not undergoing TAVR via the trans-femoral route - Carotid artery stenosis >70% in either carotid artery - Severe vascular tortuosity or anatomy that would preclude the safe introduction of the device - Aortic valve is a congenital unicuspid or congenital bicuspid valve or is non-calcified - Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation >3+) - A known contraindication or hypersensitivity to all anticoagulation regimens or an inability to undergo anticoagulation for the study procedure - History of bleeding diathesis or in whom anticoagulant and/or anti-platelet therapy is contraindicated, patients who will refuse transfusion, or havean active peptic ulcer or upper GI bleeding within the prior 3 months - Renal insufficiency, defined as a creatinine level > 221µmol/L and/or end-stage renal disease requiring chronic dialysis at time of treatment - History of stroke or transient ischemic attack (TIA) within prior 6 months - Evidence of an acute myocardial infarction (MI) within prior 30 days - Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation, or mechanical heart assistance within prior 30 days - Hypertrophic cardiomyopathy with or without obstruction - Need for emergency surgery for any reason - Severe left ventricular (LV) dysfunction with LV ejection fraction (LVEF) <20% - Severe pulmonary hypertension and right ventricular (RV) dysfunction - Echocardiographic evidence of intracardiac mass, thrombus or vegetation - Life expectancy < 12 months due to non-cardiac co-morbid conditions - Evidence of active systemic or local groin infection - Significant aortic disease, including abdominal aortic or thoracic aneurysm defined as maximal luminal diameter 5cm or greater; marked tortuosity (hyperacute bend), aortic arch atheroma or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe "unfolding" and tortuosity of the thoracic aorta - Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, or clopidogrel, or sensitivity to contrast media, that cannot be managed with premedication - Planned other cardiac surgical procedure within 2 weeks prior to, or planned cardiac surgical or interventional procedure within 30 days after the TAVR procedure. Note: Diagnostic cardiac catheterization is permitted within 10 days prior to the TAVR procedure - Neurodegenerative or other progressive neurological disease - Known allergy to any device component - Known or suspected to be pregnant or lactating - Currently enrolled in an investigational drug or device clinical study in which the primary endpoint has not occurred - Patient has other medical, social or psychological problem that in the opinion of the investigator precludes them from participating

Study Design


Related Conditions & MeSH terms


Intervention

Device:
transShield Embolic Protection System
Used for embolic protection during TAVR.

Locations

Country Name City State
New Zealand Auckland City Hospital Auckland Grafton
New Zealand Waikato Hospital Hamilton
Venezuela Ascardio Asociación Cardiovascular Centroccidental La Lara Sector La Feria
Venezuela Policlinica Metropolitana, C.A Miranda Caracas

Sponsors (1)

Lead Sponsor Collaborator
TransAortic Medical, Inc.

Countries where clinical trial is conducted

New Zealand,  Venezuela, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety - Incidence of 30-Day combined rate of the following events directly related to the transShield EPS as defined by VARC-2 Major Adverse Cardiac and Cerebrovascular Events (MACCE)
All cause mortality
All cause stroke (disabling and non-disabling)
Acute kidney injury (Stage 2 or 3)
Major vascular complications
30 day combined rate post-procedure
Primary Performance - Technical Success defined as the transShield EPS ability to perform all the following functions without adjudicated device malfunction Ability to successfully deploy the device in the correct anatomical position, in the ascending aorta without interference with TAVR procedure/devices
Ability to retrieve and remove the device intact, including no visual evidence of any filter damage
During the procedure
Secondary Safety - Incidence of minor vascular complications directly related to the transShield EPS as defined by VARC-2. As defined by VARC-2.
Incidence of peri-procedural disabling stroke as defined by a modified Rankin Scale (mRS) score of 2 or more at 30 days and an increase in at least one mRS category from an individual's pre-stroke baseline.
30 days post-procedure
See also
  Status Clinical Trial Phase
Recruiting NCT04310046 - Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial N/A
Completed NCT03332745 - Mechanism of Decompensation Evaluation - Aortic Stenosis
Recruiting NCT06008080 - Post-Market Clinical Follow Up Study With Navitor Valve
Recruiting NCT06055751 - Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
Active, not recruiting NCT04815785 - Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis N/A
Terminated NCT02202434 - Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement N/A
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Active, not recruiting NCT02903420 - A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan) N/A
Completed NCT02629328 - CardioCel Tri-leaflet Repair Study N/A
Completed NCT02306226 - Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
Completed NCT01676727 - ADVANCE Direct Aortic Study
Withdrawn NCT01648309 - Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation N/A
Completed NCT01422044 - Risk Prediction in Aortic Stenosis N/A
Withdrawn NCT00774657 - Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography N/A
Terminated NCT00535899 - Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS) N/A
Terminated NCT05070130 - OpSens PRIME CLASS
Completed NCT03314857 - China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population N/A
Completed NCT04157920 - Impact of Predilatation Between Self-expanding Valves N/A
Enrolling by invitation NCT06212050 - Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
Recruiting NCT05893082 - Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR N/A